AbbVie CEO compensated on delaying Humira competition

  • Richard Gonzalez, C.E.O. of AbbVie, told a congressional hearing that his pay was tied to the price of the company’s drug for rheumatoid arthritis and other conditions, Humira.
  • The annual per-patient cost of Humira doubled between 2012 and 2018 to $38,000.
  • In 2016 the $3.3 billion spent on the drug by Medicare and Medicaid accounted for 31 cents of every dollar spent on Humira in the U.S.
Continue reading

AbbVie is a great example of why the government is attacking pharma

  • A Humira prescription costs $38,000 a year.  In 2012, the drug cost about $19,000 a year.
  • An analysis released last month by my organization, the Initiative for Medicines, Access & Knowledge, shows that there have been an astonishing 247 patents filed on Humira.
  • There are an average of 125 patent applications filed and 71 patents granted for each of the 12 highest-grossing drugs in America.
  • 247 patent applications have been filed on Humira in the U.S. with the aim of delaying competition for 39 years.
  • In 2016 the $3.3 billion spent on the drug by Medicare and Medicaid accounted for 31 cents of every dollar spent on Humira in the U.S.

Continue reading